Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,063 JPY | -0.64% | -2.00% | +0.22% |
Apr. 18 | Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease | DJ |
Apr. 16 | Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds | MT |
Evolution of the average Target Price on Takeda Pharmaceutical Company Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Takeda Pharmaceutical Company Limited
Jefferies & Co. | |
TD Cowen | |
BofA Securities | |
Cowen | |
Morgan Stanley |
EPS Revisions
- Stock Market
- Equities
- 4502 Stock
- Consensus Takeda Pharmaceutical Company Limited